AB Science reports the outcome from the interim analysis of study AB09004 in Alzheimer’s Disease

    NEXT STORY
    Sanofi : FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis
    PREV STORY
    OSE Immunotherapeutics Announces Results of 2019 Annual Shareholder Meeting
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Immuron Appoints Gary S. Jacob, Ph.D., Experienced US Based Biotechnology Executive, as CEO

    MELBOURNE, Australia, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Immuron Limited, (IMC or the Company), ...

    author_avatar
    NASDAQ Market News

    Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ECCMID 2017

    - Oral presentation:  Phase 3 omadacycline IV-to-oral ABSSSI results (OASIS) - Poster presentation:  Health ...

    author_avatar
    NASDAQ Market News

    Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients’ quality of life

    Findings from more than 1,300 patients across 13 countries showed ITP had especially high ...

    author_avatar
    NASDAQ Market News